MTA1 and cancer: By RIP-qPCR verification, 17 of the 20 candidates showed enrichment at the MTA1-binding sites, including cancer invasiveness meditators ITGB4 and CD15127,28 (Fig. 2i and Supplementary Fig. 2e).